Impact of Infections in Patients with Acute Myeloid Leukemia Receiving Cytarabine+ Daunorubicin (7+3) Versus Azacitidine and Venetoclax during Induction Chemotherapy. IJBR [Internet]. 2025 Jan. 10 [cited 2025 Aug. 14];3(1):190-6. Available from: https://ijbr.com.pk/IJBR/article/view/469